# US 2025/0152658 A1 · Cyclic peptide for trapping interleukin-1 beta

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0152658 A1
- Document ID: US20250152658A1
- Status: Published application
- Kind: A1
- Application number: 18/944,230
- Filed: 2024-11-12
- Published: 2025-05-15
- Earliest claimed: 2023-11-14
- Assignees: Merck Sharp & Dohme Corp.
- Applicants: Merck Sharp & Dohme LLC
- Inventors: Faben A. Cruz; Danqing Feng; Yan Guo; Jennifer Hanisak; Jennifer L. Hickey; Ahmet Kekec; Bing Li; Michael Man-Chu Lo; Dmitri A. Pissarnitski; Christopher W. Plummer; Stefania Colarusso; Dipannita Kalyani; Quang T. Truong
- Web page: https://patentgrep.com/patent/US20250152658A1

## CPC

- A61K 38/08: Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07K 7/64: Cyclic peptides containing only normal peptide links
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Provided are compounds of the Formula (I), or their pharmaceutically acceptable salts, wherein X1, X2, X3, R1-R9, RA, RB, RD, A1, A2, and subscripts t and w are as herein described. The compounds and their pharmaceutically acceptable salts can trap IL-1β and are expected to have utility as therapeutic agents, for example, for treating cardiovascular disease and inflammatory disorders. The disclosure also provides pharmaceutical compositions which comprise the compounds disclosed herein or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cardiovascular disease and inflammatory disorders and for preparing pharmaceuticals for this purpose.

## Claims

### Claim 1

A compound of the Formula (I)
wherein:
R1 is
(i) R1a—C(O)N(H)—CH2CH2—O—, wherein
R1a is
(a) C1-C3 alkyl or
(b) (CH3)3N—CH2CH2-M-, wherein:
M is —CH2—, —CH2CH2—, —CH2CH2CH2—, —O—CH2CH2—, or —O—CH2CH2—O—CH2CH2—;
(ii) (CH3)3N—CH2CH2—O—;
(iii) C1, wherein C1 is:
(a) phenyl or a 5- to 6-membered monocyclic heteroaryl, wherein said 5- to 6-membered monocyclic heteroaryl contains 1 to 3 heteroatoms independently selected from the group consisting of N, O, and S;
(b) a 5- to 6-membered heterocycloalkyl, wherein said 5- to 6-membered heterocycloalkyl is saturated and contains 1 or 2 heteroatoms selected from the group consisting of N, O, and S;
wherein C1 is unsubstituted or substituted by 1 to 3 RC1 substituents independently selected from the group consisting of halo, C1-C3 alkyl, C1-C3 fluoroalkyl, carboxy, C1-C3 alkoxy, C2-C3 acyl, and C1-C3 alkoxymethyl;
(iii) (CH3)3N—CH2CH2—O—; or
(iv) a group
RA is:
(i) —CO2H;
(ii) —CO2NH2;
(iii) —S(O)2NH2; or
(iv) a 5-membered heteroaryl containing 2 or 3 heteroatoms independently selected from the group consisting of N, O, and S;
wherein the 5-membered heteroaryl is unsubstituted or substituted by 1 to 2 substituents independently selected from the group consisting of halo, C1-C3 alkyl, C1-C3 alkoxy, oxo, and C1-C3 alkoxymethyl;
RB is amino, hydroxy, or fluoro;
R2 is
(i) naphthyl; or
(ii) a 9- to 10-membered bicyclic heteroaryl, wherein said 9- to 10-membered bicyclic heteroaryl contains 1 to 2 heteroatoms independently selected from the group consisting of N, O, and S;
wherein R2 is unsubstituted or substituted by 1 to 2 R2a substituents independently selected from the group consisting of halo, C1-C3 alkyl and C1-C3 alkoxy;
R3 is —(CH2)mCO2H, —(CH2)mCO2NH2, —(CH2)mCO2N(CH3)2, —(CH2)mCH2N(H)C(O)NH2, or —(CH2)m—C3;
wherein C3 is a 5-membered heteroaryl containing 2 to 4 heteroatoms selected from the group consisting of N, O, and S;
wherein C3 is unsubstituted or substituted by 1 to 2 substituent selected from the group consisting of halo and C1-C3 alkyl;
R4 is C1-C3 alkyl;
R5 is H, C1-C3 alkyl, or —CH2CO2H;
or alternatively R4 and R5 together with the atoms to which they are attached form a pyrrolidinyl, piperidinyl or azepinyl ring;
X1, X2, and X3 are independently C(H) or N;
RD is:
(i) ring CD, wherein ring CD is:
(a) phenyl; or
(b) cyclohexyl;
wherein ring CD is substituted by one A1; wherein A1 is —CO2H, —CONH2, or —N(H)SO2CH3;
(ii) hydroxy;
(iii) —CO2NH2; or
(iv) —OCH2CH2C(O)N(H)C(O)CH3;
A2 is H, halo or C1-C3 alkyl;
R6 is —H, —NH2, —C(O)N(CH3)2; —(CH2)nNH2; —(CH2)nN(H)CH3; —(CH2)nN(CH3)3; —OH; —(CH2)nOH; —OCH3; —(CH2)nOCH3; —(CH2)nCH3; —(CH2)nN(H)C(O)NH2; —(CH2)nCH2C(O)OH; —(CH2)nN(H)C(O)CH2CH2O(CH2CH2—O)q-CH2CH2N(CH3)3; or —C6;
C6 is
(i) a 5- to 6-membered monocyclic aryl or heteroaryl, wherein said 5- to 6-membered monocyclic heteroaryl contains 1 to 3 heteroatoms independently selected from the group consisting of N, O, and S;
(ii) a 9- to 10-membered bicyclic aryl or heteroaryl, wherein said 9- to 10-membered bicyclic heteroaryl contains 1 to 4 heteroatoms independently selected from the group consisting of N, O, and S; and
(iii) a 3- to 8-membered mono- or bicyclic cycloalkyl;
wherein C6 is unsubstituted or substituted by 1 to 3 RC6 substituents independently selected from the group consisting of halo, amino, hydroxy, carboxy, C1-C3 alkyl, C1-C3 fluoroalkyl, C1-C3 alkoxy, and C1-C3 alkoxymethyl;
R7 is H, C1-C4 alkyl, —(CH2)uOH, —(CH2)uC(O)N(CH3)2, —(CH2)uN(CH3)3, —(CH2)uOCH3, —(CH2)uC(O)NC(O)NH2, —(CH2)uN(H)C(O)CH2CH2O(CH2CH2—O)v—CH2CH2N(CH3)3, or —CH2—C7;
C7 is:
(i) a 5-membered heteroaryl containing 2 to 4 heteroatoms selected from the group consisting of N, O, and S; or
(ii) a 5- to 6-membered heterocycloalkyl, wherein said 5- to 6-membered heterocycloalkyl is saturated and contains 1 O atom;
wherein C7 is unsubstituted or substituted by 1 to 2 substituents selected from the group consisting of halo, C1-C3 alkyl, C1-C3 alkoxy, and C1-C3 alkoxymethyl;
R8 is —H, —F, —OH, —NH2, —N(CH3)3, (CH3)3N—(CH2)r—C(O)—, or (CH3)3N—CH2CH2—O—(CH2CH2—O)s—CH2CH2—C(O)—
R9 is —C9 or —CH2—C9;
C9 is phenyl or a 5- to 6-membered monocyclic heteroaryl, wherein said 5- to 6-membered monocyclic heteroaryl contains 1 to 2 heteroatoms independently selected from the group consisting of N, O, and S;
wherein C9 is unsubstituted or substituted by 1 to 3 RC9 substituents independently selected from the group consisting of halo, amino, hydroxy, C1-C3 alkyl, C1-C3 fluoroalkyl, and C1-C3 alkoxy;
wherein C9 is optionally substituted by 1 ring RC9C, the ring RC9C is:
(a) phenyl; or
(b) a 5- to 6-membered monocyclic heteroaryl containing 1 to 2 heteroatoms independently selected from the group consisting of N, O, and S;
subscript m is 1 or 2;
subscript n is 1, 2, or 3; and
subscript q is 1, 2, or 3;
subscript r is 3, 4, 5, or 6;
subscript s is 1 or 2;
subscript t is 0 or 1;
subscript u is 0, 1, 2, 3, or 4;
subscript v is 1, 2, or 3; and
subscript w is 0 or 1; or
a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein:
C1 is phenyl;
R2 is indolyl or naphthyl;
C6 is phenyl, indolyl, pyridyl, pyridazinyl, or bicyclo[1.1.1]pentanyl; and
C9 is phenyl or pyrimidinyl.

### Claim 3 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R1 is CH3—C(O)N(H)—CH2CH2—O— or 4-fluorophenyl.

### Claim 4 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R2 is unsubstituted or substituted naphthyl or indolyl.

### Claim 5 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R3 is —(CH2)mCO2H.

### Claim 6 (depends on 5)

The compound of claim 5 or a pharmaceutically acceptable salt thereof, wherein subscript m is 1.

### Claim 7 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R4 and R5 are methyl.

### Claim 8 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein:
X1 and X2 are C(H) and
A1 is carboxy.

### Claim 9 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R6 is:
(i) a substituted or unsubstituted 5- to 6-membered monocyclic aryl or heteroaryl, wherein said 5- to 6-membered monocyclic heteroaryl contains 1 to 2 N atoms; or
(ii) a substituted or unsubstituted 9- to 10-membered bicyclic heteroaryl, wherein said bicyclic heteroaryl contains 1 to 2 N atoms.

### Claim 10 (depends on 9)

The compound of claim 9 or a pharmaceutically acceptable salt thereof, wherein R6 is indolyl.

### Claim 11 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R7 is H.

### Claim 12 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R8 is H or —NH2.

### Claim 13 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R9 is substituted on position 4 of the illustrated pyrrolidinyl ring.

### Claim 14 (depends on 13)

The compound of claim 13 or a pharmaceutically acceptable salt thereof, wherein C9 is substituted or unsubstituted phenyl or pyrimidinyl.

### Claim 15 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R9 is —CH2-(4-fluorophenyl) or pyrimidin-5-yl.

### Claim 16 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein:
R1 is CH3—C(O)N(H)—CH2CH2—O— or 4-fluorophenyl;
R2 is unsubstituted or substituted naphthyl or indolyl;
R3 is —(CH2)mCO2H;
R4 and R5 are methyl;
X1 and X2 are C(H);
A1 is carboxy;
A2 is H;
R6 is:
(i) a substituted or unsubstituted 5- to 6-membered monocyclic aryl or heteroaryl, wherein said 5- to 6-membered monocyclic heteroaryl contains 1 to 2 N atoms; or
(ii) a substituted or unsubstituted 9- to 10-membered bicyclic heteroaryl, wherein said 9- to 10-membered bicyclic heteroaryl contains 1 to 2 N atoms;
R7 is H;
R8 is H or —NH2; and
R9 is substituted on position 4 of the illustrated pyrrolidinyl ring.

### Claim 17 (depends on 16)

The compound of claim 16 or a pharmaceutically acceptable salt thereof, wherein:
R6 is indolyl;
R9 is —CH2-(4-fluorophenyl) or pyrimidin-5-yl, substituted on the 4-position of the illustrated pyrrolidinyl ring; and
subscript m is 1.

### Claim 18 (depends on 1)

The compound of claim 1 or the pharmaceutically acceptable salt thereof, wherein the compound of Formula (I) has Formula (IA)
wherein:
R1 is:
(i) R1a—C(O)N(H)—CH2CH2—O—, wherein R1a is:
(a) methyl; or
(b) (CH3)3N—CH2CH2—O—CH2CH2—;
(ii) (CH3)3N—CH2CH2—O—; or
(iii) 4-carboxyphenyl;
R2 is a group
R2a is halo or methyl;
subscript x is 0 or 1;
R3 is —CH2CO2H or —CH2-tetrazolyl;
R4 and R5 are methyl;
or alternatively R4 and R5 together with the atoms to which they are attached form a piperidinyl ring;
RD is 4-carboxyphenyl or hydroxy;
R6 is a group selected from:
R7 is H or methyl;
R8 is —H, —NH2, or —OH;
C9 is a group selected from

### Claim 19 (depends on 1)

The compound of claim 1 selected from the group consisting of SEQ ID NOS: 1-465, or a pharmaceutically acceptable salt thereof.

### Claim 20 (depends on 1)

The compound of claim 1 selected from the group consisting of (SEQ ID NOs: 1, 2, 78, 80, 82, 92, 94, 95, 98, 99, 100, 101, 102, 215, 216, 217, and 218, respectively):
or a pharmaceutically acceptable salt thereof.

### Claim 21 (depends on 1)

A pharmaceutical composition comprising the compound of claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

### Claim 22 (depends on 1)

A method of treating atherosclerosis, comprising administering a therapeutically effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof to a subject in need thereof.

### Claim 23 (depends on 1)

A method of treating vascular inflammation, comprising administering a therapeutically effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof to a subject in need thereof.

### Claim 24 (depends on 1)

A method of treating an inflammatory disorder, comprising administering a therapeutically effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof to a subject in need thereof.
